Vital Signs Podcast: EBR’s major milestones in WiSE CRT commercialisation

In the episode, we unpack EBR Systems’ major milestones this year and next steps in the commercial roll out of its tech.

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.

In this episode Nadine chats to John McCutcheon, the President and CEO of EBR Systems (ASX:EBR).

EBR is focused on its lead technology, the WiSE CRT System, an innovative device designed to overcome the limitations of conventional Cardiac Resynchronisation Therapy (CRT) and is the only leadless left ventricular endocardial pacing (LVEP) device on the market.

The company recently received FDA approval for the device in the US, opening the door to a mega market opportunity in one of the worlds largest healthcare markets.

Earlier this month, the first two US commercial patients were treated with WiSE ahead of the company's reimbursement milestones, further demonstrating the clinical importance of the device.

In this episode McCutcheon explains the significance of the technology, the reimbursement scheme and outlines the next steps for EBR as it prepares for commercial roll out.

This podcast was developed in collaboration with EBR Systems, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Vital Signs Podcast: EBR’s major milestones in WiSE CRT commercialisation